NUMELVI from MSD Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., […]
12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) […]
Rahway, NJ., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines. If the European Commission (EC) adopts the recommendation, the […]
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA […]
RAHWAY, NJ, May 16, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the INNOVAX®-ND-IBD-ILT vaccine. If approved, this will be the only single-dose vaccine approved in the EU to […]
Data demonstrates the benefits of vaccination for Cryptosporidium parvum disease prevention, management and herd health Rahway, N.J. – May 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the company will present more than 10 new studies at The European Buiatrics Congress and ECBHM Jubilee […]
The leading manufacturer of otic treatments expands portfolio with the only FDA-approved, one dose, in-clinic treatment for Pseudomonas aeruginosa and other pathogens RAHWAY, N.J., May 02, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of MOMETAMAX SINGLE™ […]
New vaccine reduces viraemia and clinical signs of disease caused by avian reovirus, expanding NOBILIS MULTRIVA portfolio Rahway, N.J., March 27, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced that the European Commission has granted the marketing authorization for NOBILIS MULTRIVA™ REOm for use in chickens. […]
Recombinant bovine somatotropin, manufactured by Union Agener Animal Health, increases milk production in lactating dairy cows Complements MSD Animal Health’s broad portfolio of veterinary pharmaceuticals, vaccines and technology solutions RAHWAY, N.J., Feb. 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), and Union Agener Animal Health, today […]
Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products Rahway, N.J., February 11, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that S&P Global Animal Health awarded the injectable formulation of BRAVECTO® (fluralaner) the 2024 Best New Companion […]